|Bid||2.8000 x 1100|
|Ask||5.4000 x 900|
|Day's Range||3.0400 - 3.2800|
|52 Week Range||2.3900 - 7.4700|
|Beta (3Y Monthly)||1.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
BOSTON, MA / ACCESSWIRE / March 12, 2019 / Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today reported its cash position for the fiscal year ended December 31, 2018 and provided an update on the Company's recent and future developments. ''2018 was an important year for the development of our two core franchises: respiratory diseases and immuno-oncology. On the respiratory front, we announced that PRS-060, an inhaled IL-4 receptor alpha antagonist for moderate-to-severe asthma that we are developing with AstraZeneca and our first respiratory program to enter the clinic, was safe and well-tolerated in healthy volunteers in a single ascending dose phase 1 study.
NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 12, 2019, 2018 ...
BOSTON, MA / ACCESSWIRE / March 6, 2019 / Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Stephen S. Yoder, President and Chief Executive Officer of Pieris Pharmaceuticals, Inc., will present at the Cowen and Company 39th Annual Health Care Conference in Boston on Wednesday, March 13, 2019 at 10:40 AM (EDT). Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
BOSTON, MA / ACCESSWIRE / March 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for ...
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you're interested in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), then youRead More...
The big shareholder groups in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...
CORAL GABLES, FL / ACCESSWIRE / December 21, 2018 / The pharmaceutical industry is predicated on the notion that treatments for various ailments can always be improved upon, and patients suffering from these diseases both demand and need better treatment options. As pharmaceutical companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety may benefit from these efforts. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals, Inc (SGYP), Pieris Pharmaceuticals, Inc (PIRS), and Obalon Therapeutics Inc (OBLN) are 4 pharma stocks representing companies invested in creating the best quality drug treatments for their patients.
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
Steve Yoder has been the CEO of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
P.A.W. Capital Partners is a Greenwich-based hedge fund launched at the end of 1990 by its current Chief Investment Officer, General Partner and Senior Portfolio Manager, Peter A. Wright. After leading his fund for 28 years, and considering his previous work history, Peter Wright has more than 30 years of experience in the securities industry. […]
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 26.67% and 35.54%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of 11 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...
Company to Host an Investor Conference Call on Wednesday, November 7, 2018 at 8:00 AM EST BOSTON, Nov. 07, 2018 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a.
BOSTON, Oct. 31, 2018 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology.
Pieris Pharmaceuticals Inc (NASDAQ:PIRS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PIRS Read More...